Back to Report Store Home

Pharmaceutical Lifecycle Management Strategies in 2017

  • Published: Apr-2017
  • Report Code: GBI078CBR
  • Report Format: pdf

Description

Table of Contents

Introduction

2. Executive Summary

3. Introduction to Pharmaceutical Lifecycle Management Strategies

3.1 The Pharmaceutical Product Lifecycle Curve

3.2 Key Objectives of Life Cycle Management Strategies in the Pharmaceutical Industry

3.3 What is Driving the Need for Effective Lifecycle Management Strategies in the Pharmaceutical Industry?

3.4 Classification and Benefits of Different Lifecycle Management Strategies for Pharma

3.5 Business Opportunities Created by LCM Strategies

3.6 Factors Impacting Choice of Lifecycle Strategies

4. Pharmaceutical Lifecycle Management – Commercial Strategies

4.1 Rx-to-OTC Switch as an LCM Strategy

4.1.1 RX-to-OTC Switch Case Studies

4.2 Geographical Expansion

4.3 Contract Research Organizations Helping Overcome Industry Challenges

4.3.1 Benefits from Partnering with Contract Development and Manufacturing Organizations (CDMOs)

4.3.2 Strategic Partnerships with CROs: Case studies

4.4 Pricing and Reimbursement Strategies for LCM in Pharma

4.4.1 Key Factors and Strategies to Consider when Making Pricing Decisions

4.4.2 Common Pricing Strategies in Pharma

4.4.3 A Systematic Value Development Plan to Achieve Optimum Reimbursement

4.5 Customer Retention Programs as LCM Strategies for Pharma

4.5.1 Role of Medical Publications in LCM Optimization

4.6 Asset Transactions as an LCM Tactic

4.6.1 Strategic Divestitures by Type and Recent Examples

5. Regulatory and Legal Strategies

5.1 Data Exclusivity

5.2 Orphan Drug Exclusivity

5.3 Pediatric exclusivity

6. Developmental Strategies

6.1 Introduction and Classification of Developmental Strategies

6.2 Indication Expansion

6.2.1 Key Consideration When Planning for Indication Expansion

6.2.2 Indication Expansion Case Study

6.3 Reformulation

6.3.1 Next-Generation Products: Introduction and Key Strategic Considerations

6.3.2 Types of Next-Generation Products

6.3.2.1 Metabolites

6.3.2.2 Chiral Switching

6.3.2.3 Polymorphs

6.3.3 Next-Generation Products: Case Study

6.3.4 New Modes of Drug Delivery

6.3.4.1 Dosage Form: Case study

6.3.4.2 Route of Administration: Case Study

6.3.4.3 Drug delivery technologies: Case Study

6.4 Combination Drugs

6.4.1 Combination Drugs: Case Study

7. Successful LCM Strategies Employed by Big Pharma: Case Studies

7.1 Pfizer

7.2 AstraZeneca

7.3 Teva

7.4 AbbVie

7.5 Roche & GSK

7.6 Cipla

7.7 Unsuccessful Implementation of LCM Strategies: Case Study

8. Patent Expiry Dates of Bestselling Pharmaceuticals 2005–2016

9. Life Cycle Management Strategies of Pipeline Products 2017

9.1 Eisai

9.2 Merck & Co

9.3 Johnson & Johnson

9.4 Takeda

9.5 AbbVie

10. Bibliography

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
Special Offer
Expires on 25 October 2017
15% OFF
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$2546 $2995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$5092 $5990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$7638 $8985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5817
Or click here to contact us
Secure Payments
Cards